Treatment of H. pylori infections using MTAN inhibitors
US-10118928-B2 · Nov 6, 2018 · US
Treatment of helicobacter pylori infections
US11186575B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11186575-B2 |
| Application number | US-201314419669-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 7, 2013 |
| Priority date | Aug 7, 2012 |
| Publication date | Nov 30, 2021 |
| Grant date | Nov 30, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Methods of treating infections due to Helicobacter pylori ( H. pylori ), in particular in subjects having a peptic ulcer, are disclosed where the methods comprise administering to the subject an inhibitor of H. pylori MTAN (5′-methylthioadenosine nucleosidase) having the structure of formula (I)
First claim
Opening claim text (preview).
What is claimed is: 1. A compound selected from the group consisting of or a pharmaceutically acceptable salt thereof, or an ester thereof. 2. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier. 3. A method of treating a Helicobacter pylori ( H. pylori ) infection in a subject in need thereof comprising administering to the subject a compound of claim 1 in an amount effective to inhibit growth of H. pylori. 4. The method of claim 3 , wherein the subject has a peptic ulcer. 5. The method of claim 3 , wherein the subject has a gastric ulcer or a duodenal ulcer. 6. The method of claim 3 , wherein the compound is administered orally.
Assignees
Inventors
Classifications
Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title
- C07D487/04Primary
Ortho-condensed systems · CPC title
ortho- or peri-condensed with heterocyclic rings · CPC title
for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants · CPC title
Antibacterial agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11186575B2 cover?
- Methods of treating infections due to Helicobacter pylori ( H. pylori ), in particular in subjects having a peptic ulcer, are disclosed where the methods comprise administering to the subject an inhibitor of H. pylori MTAN (5′-methylthioadenosine nucleosidase) having the structure of formula (I)
- Who is the assignee on this patent?
- Albert Einstein College Medicine Inc, Victoria Link Ltd, Alber Einslein College of Medicine
- What technology area does this patent fall under?
- Primary CPC classification C07D487/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Nov 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 6 related publications on this page (citations in our corpus or others sharing the same primary CPC).